Drugs / Subcutaneous immunoglobulin
Subcutaneous immunoglobulin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02556437 | Jun 2016 → May 2018 | multifocal motor neuropathy | Johannes Jakobsen | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04728425 Comparator | Aug 2020 → Jun 2023 | myasthenia gravis | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT01017159 Comparator | Apr 2010 → Nov 2011 | chronic inflammatory demyelinating polyradiculoneuropathy | University of Aarhus | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01412385 Background | Jun 2011 → May 2014 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-09-25 | Takeda | Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia takeda.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Subcutaneous immunoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01017159 ↗ |
| Known as | Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01412385 ↗ |
| Known as | SCIG | “subcutaneous immunoglobulin (SCIG)” NCT04728425 ↗ |
| Known as | Subcuvia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02556437 ↗ |
| Modality | Protein / enzyme biologic | “subcutaneous immunoglobulin” NCT01017159 ↗ |
| Route | Subcutaneous | “administered subcutaneously (SCIg)” NCT01017159 ↗ |